Vudalimab for Thyroid Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests vudalimab, an immunotherapy drug, in patients with advanced or metastatic anaplastic thyroid cancer or Hurthle cell thyroid cancer. Vudalimab helps the immune system fight the cancer and aims to prevent it from growing and spreading.
Do I need to stop my current medications for the trial?
The trial requires that you stop any anticancer therapies at least 1 week before starting the trial if you have anaplastic thyroid cancer, or 2 weeks before if you have Hurthle cell thyroid cancer. Additionally, you must stop taking corticosteroids or other immunosuppressive medications 14 days before the trial begins.
Is Vudalimab (XmAb717) generally safe for humans?
While specific safety data for Vudalimab (XmAb717) is not provided, similar treatments like PD-1 and PD-L1 inhibitors have been associated with thyroid-related side effects, such as hypothyroidism (underactive thyroid) and thyrotoxicosis (overactive thyroid). These side effects are usually manageable and do not typically require stopping the treatment.12345
What data supports the effectiveness of the drug Vudalimab (XmAb717) for thyroid cancer?
Who Is on the Research Team?
Jochen H Lorch, M.D.
Principal Investigator
Northwestern University
Are You a Good Fit for This Trial?
Adults with advanced or metastatic anaplastic thyroid cancer (ATC) or Hurthle cell thyroid cancer (HCC), who have tried all standard treatments without success. Participants must be in good enough health to perform daily activities, not pregnant, and willing to use contraception. They can't join if they've had certain previous therapies like CTLA4 or PD-1/PD-L1 inhibitors, are on immunosuppressants, have active brain metastases, serious infections recently, or known allergies to similar drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive vudalimab intravenously over 1 hour on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion. Follow-up occurs every 3 months for 1 year and then every 6 months for 4 years.
What Are the Treatments Tested in This Trial?
Interventions
- Vudalimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator